# Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery

Study · id `cardio:ct-nct07238972` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07238972](<https://clinicaltrials.gov/study/NCT07238972>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07238972

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07238972. Randomized; single masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2030-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07238972, source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)
- Planned start: 2025-12 (anticipated) (ClinicalTrials.gov record NCT07238972, source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)
- Primary completion: 2030-08 (anticipated) (ClinicalTrials.gov record NCT07238972, source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)
- Completion: 2030-10 (anticipated) (ClinicalTrials.gov record NCT07238972, source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07238972, source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07238972-2025-11-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery
- Condition: Anemia
- Condition: Iron Deficiencies
- Condition: Iron Deficiency Anemia
- Condition: Cardiac Surgery
- Condition: Heart Valve Diseases
- Intervention (Drug): Ferric derisomaltose
- Intervention (Drug): Placebo (0.9% saline)
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 699dc81a7314b145705642b68652d4f1f86b7df994b66df87a95ab961c02ba14
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
